Abstract
Melatonin and melatonin agonists offer novel treatments for sleep and mood disorders, particularly where circadian misalignment is also present. The therapies offer both phase-shifting and sleep-promoting effects and have shown potential to treat advanced and delayed sleep-wake phase disorder, non-24-h sleep-wake cycle, jetlag, shift work disorder, insomnia, seasonal affective disorder and major depressive disorder.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
American Psychiatric Association (2013) DSM 5. American Psychiatric Association, Washington, DC
Arendt J, Rajaratnam SMW (2008) Melatonin and its agonists: an update. Br J Psychiatry 193(4):267–269. https://doi.org/10.1192/bjp.bp.108.050955
Avery DH, Wildschiødtz G, Rafaelsen OJ (1982) Nocturnal temperature in affective disorder. J Affect Disord 4(1):61–71
Avery D, Dahl K, Savage M, Brengelmann G, Larsen L, Kenny M, Eder DN, Vitiello MV, Prinz P (1997) Circadian temperature and cortisol rhythms during a constant routine are phase-delayed in hypersomnic winter depression. Biol Psychiatry 41:1109–1123. https://doi.org/10.1016/S0006-3223(96)00210-7
Borja NL, Daniel KL (2006) Ramelteon for the treatment of insomnia. Clin Ther 28:1540–1555. https://doi.org/10.1016/j.clinthera.2006.10.016
Buckley TM, Schatzberg AF (2010) A pilot study of the phase angle between cortisol and melatonin in major depression – a potential biomarker? J Psychiatr Res 44(2):69–74. https://doi.org/10.1016/j.jpsychires.2009.06.012
Burgess HJ, Revell VL, Eastman CI (2008) A three pulse phase response curve to three milligrams of melatonin in humans. J Physiol 586(2):639–647. https://doi.org/10.1113/jphysiol.2007.143180
Burgess HJ, Revell VL, Eastman CI (2010) Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. J Clin Endocrinol Metab 95(7):3325–3331. https://doi.org/10.1210/jc.2009-2590
Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP, Vohra S (2005) The efficacy and safety of exogenous melatonin for primary sleep disorders: a meta-analysis. J Gen Intern Med 20(12):1151–1158. https://doi.org/10.1111/j.1525-1497.2005.0243.x
Cajochen C, Kräuchi K, Wirz-Justice A (1997) The acute soporific action of daytime melatonin administration: effects on the EEG during wakefulness and subjective alertness. J Biol Rhythms 12:636–643. https://doi.org/10.1177/074873049701200619
Carman JS, Post RM, Buswell R, Goodwin FK (1976) Negative effects of melatonin on depression. Am J Psychiatry 133:1181–1186
Colwell CS (2011) Linking neural activity and molecular oscillations in the SCN. Nat Rev Neurosci 12(10):553–569. https://doi.org/10.1038/nrn3086
Dahl K, Avery DH, Lewy AJ, Savage M, Brengelmann G, Larsen L, Vitiello MV, Prinz P (1993) Dim light melatonin onset and circadian temperature during a constant routine in hypersomnic winter depression. Acta Psychitar Scand 88:60–66
Dahlitz MJ, Alvarez B, Vignau J, English J, Arendt J, Parkes JD (1991) Delayed sleep-phase syndrome: response to melatonin. Lancet 337:1121–1124
Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM (2000) Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci 25:48–52
Deacon S, Arendt J (1995) Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans. Brain Res 688:77–85
Dijk DJ, Cajochen C (1997) Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. J Biol Rhythms 12(6):627–635
Dubocovich ML (2007) Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med 8(3):34–42. https://doi.org/10.1016/j.sleep.2007.10.007
Emens J, Lewy AJ, Mark J, Arntz D, Rough J (2009) Circadian misalignment in major depressive disorder. Psychiatry Res 168:259–261. https://doi.org/10.1016/j.psychres.2009.04.009
European Medicines Agency (2014) EMA confirms positive benefit-risk for antidepressant Valdoxan/Thymanax (agomelatine) [Press release]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/09/news_detail_002173.jsp&mid=WC0b01ac058004d5c1
van Geijlswijk IM, Korzilius HPLM, Smits MG (2010) The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep 33(12):1605–1614
Graw P, Werth E, Krauchi K, Gutzwiller F, Cajochen C, Wirz-Justice A (2001) Early morning melatonin administration impairs psychomotor vigilance. Behav Brain Res 121(1–2):167–172
Hickie IB, Rogers NL (2011) Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 378:621–631. https://doi.org/10.1016/S0140-6736(11)60095-0
Hughes RJ, Badia P (1997) Melatonin and sleep: sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep 20(2):124–131
Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML (2001) Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol 280(1):C110–C118. https://doi.org/10.1152/ajpcell.2001.280.1.C110
Khalsa SB, Jewett ME, Cajochen C, Czeisler CA (2003) A phase response curve to single bright light pulses in human subjects. J Physiol (Lond) 549(Pt 3):945–952
Klein DC, Moore RY (1979) Pineal N-acetyltransferase and hydroxyindole-O-methyltransferase: control by the retinohypothalamic tract and the suprachiasmatic nucleus. Brain Res 174:245–262
Krauchi K, Cajochen C, Pache M, Flammer J, Wirz-Justice A (2006) Thermoregulatory effects of melatonin in relation to sleepiness. Chronobiol Int 23(1–2):475–484. https://doi.org/10.1080/07420520500545854
Lavie P (1986) Ultrashort sleep-waking schedule. III. ‘Gates’ and ‘forbidden zones’ for sleep. Electroencephalogr Clin Neurophysiol 63(5):414–425
Lavie P (1997) Melatonin: role in gating nocturnal rise in sleep propensity. J Biol Rhythms 12:657–665
Lemoine P, Guilleminault C, Alvarez E (2007a) Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 68:1723–1732
Lemoine P, Nir T, Laudon M, Zisapel N (2007b) Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 16:372–380
Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W (1958) Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 80(10):2587
Lewy A (2010) Clinical implications of the melatonin phase response curve. J Clin Endocrinol Metab 95(7):3158–3160. https://doi.org/10.1210/jc.2010-1031
Lewy AJ, Sack RL, Singer CM (1985) Immediate and delayed effects of bright light on human melatonin production: shifting “dawn” and “dusk” shifts the dim light melatonin onset (DLMO). Ann N Y Acad Sci 453:253–259
Lewy A, Lefler BJ, Emens J, Bauer VK (2005a) The circadian basis of winter depression. Proc Natl Acad Sci 103(19):7414–7419. https://doi.org/10.1073/pnas.0602425103
Lewy AJ, Emens JS, Lefler BJ, Bauer VK (2005b) In winter depression (SAD), the sweet spot for the 10pg/mL plasma dim light melatonin onset (DLMO) is six hours before mid-sleep. Neuropsychopharmacology 30:562–563
Lewy AJ, Emens JS, Lefler BJ, Yuhas K, Jackman AR (2005c) Melatonin entrains free-running blind people according to a physiological dose-response curve. Chronobiol Int 22:1093–1106. https://doi.org/10.1080/07420520500398064
Lewy AJ, Emens J, Jackman A, Yuhas K (2006) Circadian uses of melatonin in humans. Chronobiol Int 23(1–2):403–412. https://doi.org/10.1080/07420520500545862
Li SX, Liu LJ, Xu LZ, Gao L, Wang XF, Zhang JT, Lu L (2013) Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment. Psychoneuroendocrinology 38:2789–2799. https://doi.org/10.1016/j.psyneuen.2013.07.009
Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM (1997) Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19(1):91–102
Liu C, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML (2016) MT1 and MT2 melatonin receptors: a therapeutic perspective. Annu Rev Phamacol Toxicol 56:361–383. https://doi.org/10.1146/annurev-pharmtox-010814-124742
Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, Hull JT, Torres R, Polymeropoulos MH (2015) Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet 386(10005):1754–1764. https://doi.org/10.1016/s0140-6736(15)60031-9
Lynch H, Wurtman R, Moskowitz M, Archer M, Ho M (1975) Daily rhythm in human urinary melatonin. Science 187:169–171
Mundey K, Benloucif S, Harsanyi K, Dubocovich ML, Zee P (2005) Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep 28(10):1271–1278
Murray JM, Sletten T, Magee M, Gordon C, Lovato N, Bartlett DJ, Kennaway D, Lack LC, Grunstein RR, Lockley SW, Rajaratnam SM, Delayed Sleep on Melatonin (DelSoM) Study Group (2017) Prevalence of circadian misalignment and its association with depressive symptoms in delayed sleep phase disorder. Sleep 40(1). https://doi.org/10.1093/sleep/zsw002
Naismith SL, Hermens DF, Ip TK, Bolitho S, Scott E, Rogers NL, Hickie IB (2012) Circadian profiles in young people during the early stages of affective disorder. Transl Psychiatry 2:e123. https://doi.org/10.1038/tp.2012.47
Nickelsen T, Samel A, Vejvoda M, Wenzel J, Smith B, Gerzer R (2002) Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-controlled trial. Chronobiol Int 19(5):915–936
Olié JP, Kasper S (2007) Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10(5):661–673. https://doi.org/10.1017/S1461145707007766
Oren DA, Turner EH, Wehr TA (1995) Abnormal circadian rhythm of plasma melatonin and body temperature in the delayed sleep phase syndrome. J Neurol Neurosurg Psychiatry 58:379
Perreau-Lenz S, Kalsbeek A, Garidou ML, Wortel J, van der Vliet J, van Heijningen C, Simonneaux V, Pévet P, Buijs RM (2003) Suprachiasmatic control of melatonin synthesis in rats: inhibitory and stimulatory mechanisms. Eur J Neurosci 17(2):221–228
Perreau-Lenz S, Kalsbeek A, Pevet P, Buijs RM (2004) Glutamatergic clock output stimulates melatonin synthesis at night. Eur J Nuerosci 19:318–324
Quera-Salva MA, Lemoine P, Guilleminault C (2010) Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol 25(3):222–229. https://doi.org/10.1002/hup.1112
Rahman SA, Kayumov L, Shapiro CM (2010) Antidepressant action of melatonin in the treatment of delayed sleep phase syndrome. Sleep Med 11(2):131–136. https://doi.org/10.1016/j.sleep.2009.07.013
Rajaratnam SMW, Arendt J (2001) Health in the 24-hour society. Lancet 358:999–1005. https://doi.org/10.1016/S0140-6736(01)06108-6
Rajaratnam SMW, Dijk DJ, Middleton B, Stone BM, Arendt J (2003) Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-h production of reproductive hormones. J Clin Endocrinol Metab 88:4303–4309. https://doi.org/10.1210/jc.2003-030460
Rajaratnam SMW, Middleton B, Stone BM, Arendt J, Dijk DJ (2004) Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol 561(Pt 1):339–351. https://doi.org/10.1113/jphysiol.2004.073742
Rajaratnam SMW, Cohen DA, Rogers NL (2009a) Melatonin and melatonin analogues. Sleep Med Clin 4:179–193. https://doi.org/10.1016/j.jsmc.2009.02.007
Rajaratnam SMW, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB (2009b) Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 373(9662):482–491. https://doi.org/10.1016/s0140-6736(08)61812-7
Rajaratnam SMW, Licamele L, Birznieks G (2015) Delayed sleep phase disorder risk is associated with absenteeism and impaired functioning. Sleep Health 1(2):121–127. https://doi.org/10.1016/j.sleh.2015.03.001
Redman JR (1997) Circadian entrainment and phase shifting in mammals with melatonin. J Biol Rhythms 12(6):581–587
Reppert SM, Perlow MJ, Ungerleider LG et al (1981) Effects of damage to the suprachiasmatic area of the anterior hypothalamus on the daily melatonin and cortisol rhythms in the rhesus monkey. J Neurosci 1:1414–1425
Reppert SM, Weaver DR, Godson C (1996) Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol Sci 17(3):100–102
Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P (2006) Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 7(4):312–318. https://doi.org/10.1016/j.sleep.2006.01.003
Sack RL, Stevenson J, Lewy AJ (1990) Entrainment of a previously free-running blind human with melatonin administration. Sleep Res 19:404
Sack RL, Hughes RJ, Edgar DM, Lewy AJ (1997) Sleep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms? Sleep 20(10):908–915
Sack RL, Brandes RL, DeJongh EA, Pen S, Nordstrom S, Lewy AJ (1999a) Melatonin entrains free-running circadian rhythms in a totally blind person. Sleep 22:S138
Sack RL, Brandes RL, Lewy AJ (1999b) Totally blind people with free-running circadian rhythms can be normally entrained with melatonin. Sleep Res Online 2:624
Sack RL, Brandes RW, Kendall AR, Lewy AJ (2000) Entrainment of freerunning circadian rhythms by melatonin in blind people. N Engl J Med 343:1070–1077. https://doi.org/10.1056/NEJM200010123431503
Sharkey KM, Eastman CI (2002) Melatonin phase shifts human circadian rhythms in a placebo-controlled simulated night-work study. Am J Physiol Regul Integr Comp Physiol 282(2):R454–R463. https://doi.org/10.1152/ajpregu.00135.2001
Shekleton JA, Rajaratnam SMW, Gooley JJ, Van Reen E, Czeisler CA, Lockley SW (2013) Improved neurobehavioral performance during the wake maintenance zone. J Clin Sleep Med 9(4):353–362. https://doi.org/10.5664/jcsm.2588
Shibata S, Cassone VM, Moore RY (1989) Effects of melatonin on neuronal activity in the rat suprachiasmatic nucleus in vitro. Neurosci Lett 97(1–2):140–144
Souêtre E, Salvati E, Belugou JL, Pringuey D, Candito M, Krebs B, Ardisson JL, Darcourt G (1989) Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 28:263–278
Stehle J, Vanecek J, Vollrath L (1989) Effects of melatonin on spontaneous electrical activity of neurons in rat suprachiasmatic nuclei: an in vitro iontophoretic study. J Neural Transm 78(2):173–177
Strogatz SH, Kronauer RE, Czeisler CA (1987) Circadian pacemaker interferes with sleep onset at specific times each day: role in insomnia. Am J Physiol 253(1):R172–R178
Szuba MP, Guze BH, Baxter LRJ (1997) Electroconvulsive therapy increases circadian amplitude and lowers core body temperature in depressed subjects. Biol Psychiatry 42(12):1130–1137
Vandewalle G, Middleton B, Rajaratnam SMW, Stone BM, Thorleifsdottir B, Arendt J, Dijk DJ (2007) Robust circadian rhythm in heart rate and its variability: influence of exogenous melatonin and photoperiod. J Sleep Res 16(2):148–155. https://doi.org/10.1111/j.1365-2869.2007.00581.x
Wyatt JK, Dijk D, Ritz-De Cecco A, Ronda JM, Czeisler C (2006) Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 29(5):609–618
Zemlan FP, Mulchahey JJ, Scharf MB, Mayleben DW, Rosenberg R, Lankford A (2005) The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 66(3):384–390
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Alston, M., Cain, S.W., Rajaratnam, S.M.W. (2018). Advances of Melatonin-Based Therapies in the Treatment of Disturbed Sleep and Mood. In: Landolt, HP., Dijk, DJ. (eds) Sleep-Wake Neurobiology and Pharmacology . Handbook of Experimental Pharmacology, vol 253. Springer, Cham. https://doi.org/10.1007/164_2018_139
Download citation
DOI: https://doi.org/10.1007/164_2018_139
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-11270-7
Online ISBN: 978-3-030-11272-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)